AU2007220825B2 - Compositions and methods for modulating hemostasis using variant forms of activated Factor V - Google Patents

Compositions and methods for modulating hemostasis using variant forms of activated Factor V Download PDF

Info

Publication number
AU2007220825B2
AU2007220825B2 AU2007220825A AU2007220825A AU2007220825B2 AU 2007220825 B2 AU2007220825 B2 AU 2007220825B2 AU 2007220825 A AU2007220825 A AU 2007220825A AU 2007220825 A AU2007220825 A AU 2007220825A AU 2007220825 B2 AU2007220825 B2 AU 2007220825B2
Authority
AU
Australia
Prior art keywords
hemophilia
activated form
nucleic acid
fvl
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007220825A
Other languages
English (en)
Other versions
AU2007220825A1 (en
Inventor
Valder R. Arruda
Rodney M. Camire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of AU2007220825A1 publication Critical patent/AU2007220825A1/en
Application granted granted Critical
Publication of AU2007220825B2 publication Critical patent/AU2007220825B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2007220825A 2006-02-23 2007-02-23 Compositions and methods for modulating hemostasis using variant forms of activated Factor V Ceased AU2007220825B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77612406P 2006-02-23 2006-02-23
US60/776,124 2006-02-23
PCT/US2007/062720 WO2007101106A2 (en) 2006-02-23 2007-02-23 Compositions and methods for modulating hemostasis using variant forms of activated factor v

Publications (2)

Publication Number Publication Date
AU2007220825A1 AU2007220825A1 (en) 2007-09-07
AU2007220825B2 true AU2007220825B2 (en) 2013-02-21

Family

ID=38459752

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007220825A Ceased AU2007220825B2 (en) 2006-02-23 2007-02-23 Compositions and methods for modulating hemostasis using variant forms of activated Factor V

Country Status (7)

Country Link
US (2) US8236764B2 (cg-RX-API-DMAC7.html)
EP (2) EP1986681A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009528293A (cg-RX-API-DMAC7.html)
AU (1) AU2007220825B2 (cg-RX-API-DMAC7.html)
CA (1) CA2641519A1 (cg-RX-API-DMAC7.html)
IL (1) IL193306A (cg-RX-API-DMAC7.html)
WO (1) WO2007101106A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2365822B1 (en) * 2008-11-21 2015-07-01 The Children's Hospital Of Philadelphia Snake factor v and methods of use as a procoagulant
WO2012031240A2 (en) * 2010-09-03 2012-03-08 Richard Jenny Therapeutics for trauma induced factor v consumptive coagulopathy
US8637448B2 (en) * 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
EP2766036B1 (en) * 2011-10-13 2018-04-25 The Children's Hospital of Philadelphia Compositions and methods for modulating thrombin generation
AR101185A1 (es) * 2014-07-11 2016-11-30 Novo Nordiks As Anticuerpos anti-factor v o factor v activado
EP3691673A4 (en) 2017-10-05 2021-06-09 Epivax, Inc. REGULATORY T-LYMPHOCYTE EPITOPES
WO2019210187A1 (en) * 2018-04-26 2019-10-31 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of hemophilia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
EP0708658A4 (en) 1993-04-16 1997-05-21 Wistar Inst RECOMBINANT CYTOMEGALOVIRUS VACCINE
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
EP0760682A4 (en) 1995-02-28 1998-09-09 Univ California ANGIOGENIC THERAPY BY GENE TRANSFER
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
WO2003100053A1 (en) * 2002-05-22 2003-12-04 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia a

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHLACHTERMAN, A. et al 2005 JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 3, no. 12, pp. 2730-2737 *
TOSO, R. et al 2004 JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 20, pp. 21643-21650 *

Also Published As

Publication number Publication date
EP2384764A2 (en) 2011-11-09
EP2384764A3 (en) 2012-02-08
EP1986681A4 (en) 2010-08-04
JP2009528293A (ja) 2009-08-06
US8236764B2 (en) 2012-08-07
US8470557B2 (en) 2013-06-25
WO2007101106A2 (en) 2007-09-07
US20090318344A1 (en) 2009-12-24
AU2007220825A1 (en) 2007-09-07
IL193306A (en) 2013-04-30
EP1986681A2 (en) 2008-11-05
IL193306A0 (en) 2011-08-01
WO2007101106A3 (en) 2008-11-27
CA2641519A1 (en) 2007-09-07
US20120288895A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
US10442850B2 (en) Compositions and methods for enhancing coagulation factor VIII function
US8470557B2 (en) Isolated nucleic acids encoding activated factor V and methods for production thereof
AU2012315516B2 (en) Compositions and methods for modulating hemostasis
US10676731B2 (en) Compositions and methods for modulating factor IX function
JP7181855B2 (ja) 第ｉｘ因子の機能を調節するための組成物及び方法
JP7576039B2 (ja) 第ｉｘ因子バリアントおよび治療でのその使用
US20220403005A1 (en) Compositions and methods for modulating factor viii function
US9914918B2 (en) FVII polypeptide variants exhibiting altered interaction with endothelial protein C receptor (EPCR) and methods of use thereof for modulating hemostasis
US20250250322A1 (en) Compositions and methods for modulating factor viii function
WO2018037217A1 (en) Clotting factor
JP2025541131A (ja) 第ｖｉｉｉ因子機能を調節するための組成物及び方法
HK40077058A (en) Compositions and methods for modulating factor viii function

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired